A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Trial ID or NCT#
Status
Purpose
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Eligibility Criteria
- For the idiopathic pulmonary fibrosis (IPF) Cohort
- * Diagnosis of IPF within 7 years of screening* Female and males ≥ 40 years of age
- For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
- * Evidence of progressive ILD within the 24 months before screening* Female and male ≥ 21 years of age.
- * Women of childbearing potential (WOCBP)* Active Smokers* Current malignancy or previous malignancy up to 5 years prior to screening* History of allergy to BMS-986278 or related compounds
- Other protocol-defined inclusion/exclusion criteria apply
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Rishi Raj, Site 0043
650-736-8083
View on ClinicalTrials.gov